PartnershipUpdated on 6 June 2026
Nucleic Acid Medicines Partnership
VP, Strategic Partnerships at Eyam Health
About
Eyam Health seeks co-development and licensing partnerships with Japanese pharma and biotech in nucleic acid medicines.
Our Gemini platform is a carrier-optional self-amplifying plasmid that enables six-plus months of therapeutic protein expression from a single injection, while our Jennerator AI engine optimizes nucleic acid sequences for any target.
The foundational vector is described in Nature Communications.
Validated through Gates Foundation-funded programs and existing pharma partnerships, we invite partners to co-develop candidates, access platform licenses, or structure research collaborations advancing biologics for infectious disease, chronic conditions, and oncology.
Similar opportunities
Investment
Series A Investment Opportunity in Next-Generation Nucleic Acid Medicines
Pamela Housh
VP, Strategic Partnerships at Eyam Health
Partnership
Seeking Pharma Co-Development Partner | World's First RAGE-Targeted ADC | Solid Tumour Oncology
- Research
- Business
- Joint development
Gareth Morgan
CEO at Viamab Therapeutics L